First Time Loading...

Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 15.47 USD 1.05% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

VRNA's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. [ Read More ]

The intrinsic value of one VRNA stock under the Base Case scenario is 32.9 USD. Compared to the current market price of 15.47 USD, Verona Pharma PLC is Undervalued by 53%.

Key Points:
VRNA Intrinsic Value
Base Case
32.9 USD
Undervaluation 53%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Verona Pharma PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling VRNA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Verona Pharma PLC

Provide an overview of the primary business activities
of Verona Pharma PLC.

What unique competitive advantages
does Verona Pharma PLC hold over its rivals?

What risks and challenges
does Verona Pharma PLC face in the near future?

Has there been any significant insider trading activity
in Verona Pharma PLC recently?

Summarize the latest earnings call
of Verona Pharma PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Verona Pharma PLC.

Provide P/S
for Verona Pharma PLC.

Provide P/E
for Verona Pharma PLC.

Provide P/OCF
for Verona Pharma PLC.

Provide P/FCFE
for Verona Pharma PLC.

Provide P/B
for Verona Pharma PLC.

Provide EV/S
for Verona Pharma PLC.

Provide EV/GP
for Verona Pharma PLC.

Provide EV/EBITDA
for Verona Pharma PLC.

Provide EV/EBIT
for Verona Pharma PLC.

Provide EV/OCF
for Verona Pharma PLC.

Provide EV/FCFF
for Verona Pharma PLC.

Provide EV/IC
for Verona Pharma PLC.

Show me price targets
for Verona Pharma PLC made by professional analysts.

What are the Revenue projections
for Verona Pharma PLC?

How accurate were the past Revenue estimates
for Verona Pharma PLC?

What are the Net Income projections
for Verona Pharma PLC?

How accurate were the past Net Income estimates
for Verona Pharma PLC?

What are the EPS projections
for Verona Pharma PLC?

How accurate were the past EPS estimates
for Verona Pharma PLC?

What are the EBIT projections
for Verona Pharma PLC?

How accurate were the past EBIT estimates
for Verona Pharma PLC?

Compare the revenue forecasts
for Verona Pharma PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Verona Pharma PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Verona Pharma PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Verona Pharma PLC compared to its peers.

Compare the P/E ratios
of Verona Pharma PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Verona Pharma PLC with its peers.

Analyze the financial leverage
of Verona Pharma PLC compared to its main competitors.

Show all profitability ratios
for Verona Pharma PLC.

Provide ROE
for Verona Pharma PLC.

Provide ROA
for Verona Pharma PLC.

Provide ROIC
for Verona Pharma PLC.

Provide ROCE
for Verona Pharma PLC.

Provide Gross Margin
for Verona Pharma PLC.

Provide Operating Margin
for Verona Pharma PLC.

Provide Net Margin
for Verona Pharma PLC.

Provide FCF Margin
for Verona Pharma PLC.

Show all solvency ratios
for Verona Pharma PLC.

Provide D/E Ratio
for Verona Pharma PLC.

Provide D/A Ratio
for Verona Pharma PLC.

Provide Interest Coverage Ratio
for Verona Pharma PLC.

Provide Altman Z-Score Ratio
for Verona Pharma PLC.

Provide Quick Ratio
for Verona Pharma PLC.

Provide Current Ratio
for Verona Pharma PLC.

Provide Cash Ratio
for Verona Pharma PLC.

What is the historical Revenue growth
over the last 5 years for Verona Pharma PLC?

What is the historical Net Income growth
over the last 5 years for Verona Pharma PLC?

What is the current Free Cash Flow
of Verona Pharma PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Verona Pharma PLC.

Financials

Balance Sheet Decomposition
Verona Pharma PLC

Current Assets 289.7m
Cash & Short-Term Investments 271.8m
Receivables 11m
Other Current Assets 7m
Non-Current Assets 18.4m
Long-Term Investments 15m
PP&E 2.9m
Intangibles 545k
Current Liabilities 8.7m
Accounts Payable 3.5m
Accrued Liabilities 4.8m
Other Current Liabilities 435k
Non-Current Liabilities 50.1m
Long-Term Debt 48.4m
Other Non-Current Liabilities 1.8m
Efficiency

Earnings Waterfall
Verona Pharma PLC

Revenue
0 USD
Operating Expenses
-67.6m USD
Operating Income
-67.6m USD
Other Expenses
13.2m USD
Net Income
-54.4m USD

Free Cash Flow Analysis
Verona Pharma PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

VRNA Profitability Score
Profitability Due Diligence

Verona Pharma PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Verona Pharma PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

VRNA Solvency Score
Solvency Due Diligence

Verona Pharma PLC's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
74/100
Solvency
Score

Verona Pharma PLC's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VRNA Price Targets Summary
Verona Pharma PLC

Wall Street analysts forecast VRNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRNA is 34.53 USD with a low forecast of 31.31 USD and a high forecast of 39.9 USD.

Lowest
Price Target
31.31 USD
102% Upside
Average
Price Target
34.53 USD
123% Upside
Highest
Price Target
39.9 USD
158% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

VRNA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

VRNA Price
Verona Pharma PLC

1M 1M
-6%
6M 6M
+17%
1Y 1Y
-28%
3Y 3Y
+107%
5Y 5Y
+144%
10Y 10Y
+15%
Annual Price Range
15.47
52w Low
11.94
52w High
23.43
Price Metrics
Average Annual Return 66.05%
Standard Deviation of Annual Returns 124.7%
Max Drawdown -70%
Shares Statistics
Market Capitalization 1.3B USD
Shares Outstanding 80 983 904
Percentage of Shares Shorted 8.46%

VRNA Return Decomposition
Main factors of price return

What is price return decomposition?

VRNA News

Last Important Events
Verona Pharma PLC

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Verona Pharma PLC

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Verona Pharma PLC Logo
Verona Pharma PLC

Country

United Kingdom

Industry

Pharmaceuticals

Market Cap

1.3B USD

Dividend Yield

0%

Description

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm's product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the enzyme's phosphodiesterase 3 and 4 (PDE3 and PDE4), which is designed to act as both a bronchodilator and an anti-inflammatory agent. The firm is developing ensifentrine in three formulations for mostly used inhalation devices, such as nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The company is evaluating nebulized ensifentrine in a Phase III clinical program ENHANCE (Ensifentrine as an inhaled nebulized chronic obstructive pulmonary disease (COPD) therapy) for COPD maintenance treatment. Verona Pharma, Inc. is its wholly owned subsidiary.

Contact

London
Riverside, 3 More London Place
+114402032834200.0
http://www.veronapharma.com/

IPO

2005-03-30

Employees

24

Officers

President, CEO & Executive Director
Dr. David S. Zaccardelli Pharm.D.
Chief Financial Officer
Mr. Mark W. Hahn
Chief Medical Officer
Dr. Kathleen A. Rickard M.D.
General Counsel
Mr. Andrew Fisher
Director of Communications
Ms. Victoria Stewart
VP of Sales, Marketing & Training
Mr. Matthew Casbon
Show More
Senior Vice President of Human Resources
Ms. Ostra Jewell
Chief Development Officer
Dr. Tara Rheault M.P.H., Ph.D.
Chief Commercial Officer
Mr. Christopher Martin
Senior Vice President of Regulatory Affairs
Ms. Caroline Diaz
Show Less

See Also

Discover More
What is the Intrinsic Value of one VRNA stock?

The intrinsic value of one VRNA stock under the Base Case scenario is 32.9 USD.

Is VRNA stock undervalued or overvalued?

Compared to the current market price of 15.47 USD, Verona Pharma PLC is Undervalued by 53%.